Here, we elucidate the mechanism of cell death associated with the increased expression of soluble AZGP1 and report its potential as a predictive biomarker for therapeutic response to 5-FU treatment, as well as an immune activator in enhancing the efficacy of anti-cancer therapies. This evidence concerns the gene AZGP1 and cancer.